Galderma Reported Long-Term Nemluvio Efficacy Data
New clinical findings show sustained symptom relief for patients with atopic dermatitis and prurigo nodularis.
Updated on Oct. 8, 2026 in Allergies
Live Poll
Does long-term clinical data make you more likely to trust new treatments for chronic skin conditions?
Galderma has presented three-year clinical data for Nemluvio, showing sustained skin lesion and itch improvements in patients with atopic dermatitis and prurigo nodularis. The findings from the ARCADIA long-term extension study demonstrate the drug's safety and efficacy profile over 152 weeks of treatment.
Why it matters
These results provide critical long-term evidence for the use of Nemluvio, a monoclonal antibody that inhibits IL-31 signaling, in treating chronic inflammatory skin conditions. The data aim to establish the durability of the treatment for patients requiring ongoing management of moderate-to-severe disease.
In a study of 1,903 patients, 80 percent achieved a 90 percent improvement in disease severity and an itch-free state at Week 152. Additionally, prurigo nodularis patients showed sustained improvements through 148 weeks of treatment.
The players
Galderma
This Swiss pharmaceutical company specializes in dermatology and maintains its corporate headquarters in Zug, Switzerland.
Nemluvio
This monoclonal antibody treatment inhibits IL-31 signaling to address chronic skin conditions characterized by severe itching.
The details
The analysis evaluated 295 patients who showed an early clinical response by Week 16 and continued the treatment through the long-term extension phase. Researchers observed improvements across skin health, itch reduction, and overall quality of life for both adult and adolescent study participants.
Timeline
Galderma obtained exclusive development rights for nemolizumab in 2016.
Phase II pediatric data were presented at AAD 2026 on March 27-31, 2026.
The Fall Clinical Dermatology Conference occurred in Las Vegas from October 8-11, 2026.
A company-sponsored product theatre session took place on October 9, 2026.
The Big Picture
The findings from the ARCADIA long-term extension study update the established efficacy profile of nemolizumab for chronic pruritic conditions. By tracking patient outcomes over 152 weeks, this research extends the evidence base for IL-31 inhibitors in long-term dermatological care.
Patients with moderate-to-severe atopic dermatitis may see more reliable long-term expectations for symptom management based on these extended clinical results. These findings reinforce the viability of IL-31 targeted therapy as a durable option for controlling skin lesions and chronic itch.
The takeaway
These findings underscore the importance of long-term extension studies in confirming that dermatological treatments can provide sustained relief beyond initial clinical trials. Patients and providers can utilize this 152-week data to better assess the long-term management of chronic skin severity.
Further reading
For more information on chronic skin treatments, visit the Allergies section.
Live Poll
Does long-term clinical data make you more likely to trust new treatments for chronic skin conditions?
